Market
UroMems eyes regulatory filings for SUI treatment after $60m fundraise
UroMems raised $60 million in funding to advance its UroActive system toward regulatory submission for stress urinary incontinence treatment. The company plans to use the capital to complete a pivotal trial supporting FDA and CE mark applications in the US and Europe.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network